CD Alfacalcidol study

The study of effect of Alfacalcidol treatment on Crohn's disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041180126

Enrollment

Registered

2019-03-23

Start date

2017-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

administration of alfacalcidol for patietns with active lesion of small intestine by CE and low 25OHD level.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Crohn's disease CDAI less than 220 no steroids use

Exclusion criteria

Exclusion criteria: patients with miled or severe active lesion in the colon use of vitamin D supplement and medicine including Mg, Digitalis, PTH preparations, steroids, anti-tuberculosis drugs pregnancy

Design outcomes

Primary

Measure	Time frame
Percentage of groups showing endoscopic improvement after 3 months administration of Alfacalcidol (response rate)	—

Secondary

Measure	Time frame
response rates after 3 month endoscopic score, clinical score, clinical date, microbiota relationship between endoscopic score and vitamin D	—

Contacts

Public ContactTsunaki Sawada

Nagoya univesity hospital

t.sawada@med.nagoya-u.ac.jp+81-527442172

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026